The first‐line IBD therapy – the tumor necrotic factor (TNF) blockers – fail to induce therapeutic responses in up to 40% of the patients, and ≈23–46% of the patients experience the loss of therapeutic responses after one year.[6, 7] Although most IBD treatments are generally well tolerated, unforeseen and serious adverse events still occur in clinical treatments, leading to therapy discontinuation in more than 20% of the patients.[8]. The gene discussed is TNF; the disease is inflammatory bowel disease.